Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Lawrence Eichenfield

Pediatric Dermatology San Diego, CA Medical Doctor

NPI 1477624138 CMS profile 339077

3030 Childrens Way, San Diego, CA 92123

Open in the dashboard

General payments

$2,846,877

1,715 records reported · program years 2019–2025

Research payments

$144,132

Paid to them · 178 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$530,447 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Lawrence Eichenfield of San Diego, CA is reported in the CMS Open Payments database as having received $2,846,877 across 1,715 general payments and $144,132 in research payments paid to them. Separately, studies naming them as principal investigator received $530,447 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Pediatric Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

14 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $428,714 321
2025 Research $22,323 24
2024 General $575,493 310
2024 Research $25,086 30
2023 General $371,085 258
2023 Research $26,185 33
2022 General $285,069 223
2022 Research $22,412 23
2021 General $342,692 114
2021 Research $23,443 43
2020 General $415,170 120
2020 Research $16,081 16
2019 General $428,655 369
2019 Research $8,603 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lawrence Eichenfield
  • Pediatric Dermatology median
  • Middle half of Pediatric Dermatology
  • National median

In program year 2025, general payments to Lawrence Eichenfield were reported at $428,714. Among 172 Pediatric Dermatology profiles paid that year, the median was $302 and the middle half received between $110 and $2,128.

Show as a table
Year Lawrence Eichenfield Pediatric Dermatology median Middle half National median
2019 $428,655 $280 $89–$1,853 $163
2020 $415,170 $263 $71–$2,376 $114
2021 $342,692 $227 $69–$1,800 $132
2022 $285,069 $289 $69–$1,516 $149
2023 $371,085 $537 $114–$3,255 $160
2024 $575,493 $437 $114–$2,693 $164
2025 $428,714 $302 $110–$2,128 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Genzyme Corporation $652,537 226 payments
  2. Pfizer Inc. $536,100 168 payments
  3. LEO Pharma AS $225,880 174 payments
  4. Regeneron Healthcare Solutions, Inc. $197,191 136 payments
  5. Incyte Corporation $177,987 194 payments
  6. Sanofi-Aventis U.S. LLC $142,687 48 payments
  7. Eli Lilly and Company $129,801 74 payments
  8. LEO Pharma Inc. $100,631 51 payments
  9. AbbVie, Inc. $91,529 135 payments
  10. Arcutis Biotherapeutics, Inc. $64,467 39 payments
  11. Other $528,067 470 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $1,603,995 364 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $874,676 249 payments
  3. Travel and Lodging $194,371 475 payments
  4. Honoraria $122,017 22 payments
  5. Food and Beverage $30,625 593 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $17,850 5 payments
  7. Grant $3,318 6 payments
  8. Education $25 1 payment
Products named General payments · program years 2019–2025
  1. DUPIXENT Immunology $510,564 178 payments
  2. DUPIXENT Inflammation And Immunology $206,524 139 payments
  3. EUCRISA $202,754 52 payments
  4. OPZELURA $103,869 86 payments
  5. CIBINQO $100,350 48 payments
  6. EBGLYSS $78,296 40 payments
  7. Zoryve $60,761 35 payments
  8. DUPIXENT Immunology $40,224 41 payments
  9. VTAMA $35,819 40 payments
  10. RINVOQ $30,014 33 payments
  11. Other $301,001 341 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Regeneron Pharmaceuticals, Inc. $62,704 94 payments
  2. Pfizer Inc. $61,780 58 payments
  3. Amgen Inc. $10,125 1 payment
  4. Genzyme Corporation $8,500 22 payments
  5. LEO Pharma AS $850 2 payments
  6. Sanofi-Aventis U.S. LLC $173 1 payment

Records

1,893 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Dermatology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record